Compass Pathways Plc ADR (CMPS)

Apr 22, 2025, 6:00 AM EDT - 2 days ago

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Mar 28, 2025, 5:01 PM EDT - 26 days ago

This Is a Test From GlobeNewswire

ALVO

Mar 26, 2025, 6:30 AM EDT - 4 weeks ago

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Mar 18, 2025, 6:30 AM EDT - 5 weeks ago

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Mar 11, 2025, 6:30 AM EDT - 6 weeks ago

Compass Pathways to Participate in Stifel Virtual CNS Forum

Feb 28, 2025, 5:08 PM EST - 7 weeks ago

Compass Pathways: Betting On The Future Of Psilocybin Therapy

Feb 27, 2025, 4:02 PM EST - 7 weeks ago

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says

Feb 27, 2025, 10:41 AM EST - 2 months ago

COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:30 AM EST - 2 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Feb 25, 2025, 4:00 PM EST - 2 months ago

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 6:30 AM EST - 2 months ago

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Feb 5, 2025, 6:30 AM EST - 2 months ago

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 6:30 AM EST - 3 months ago

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Jan 10, 2025, 7:01 AM EST - 3 months ago

Compass Pathways Announces Pricing of Underwritten Offering

Dec 18, 2024, 6:30 AM EST - 4 months ago

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Nov 25, 2024, 4:00 PM EST - 5 months ago

Compass Pathways to Participate in December Investor Conferences

Nov 14, 2024, 7:44 AM EST - 5 months ago

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 6:58 AM EST - 6 months ago

Top 3 Health Care Stocks You'll Regret Missing In November

PACS SGHT

Nov 1, 2024, 5:10 PM EDT - 6 months ago

Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity

Oct 31, 2024, 2:49 PM EDT - 6 months ago

COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 6:30 AM EDT - 6 months ago

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Oct 24, 2024, 6:30 AM EDT - 6 months ago

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Sep 23, 2024, 7:00 AM EDT - 7 months ago

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Aug 28, 2024, 6:00 AM EDT - 8 months ago

Compass Pathways to participate in three investor conferences in September

Aug 15, 2024, 12:30 PM EDT - 8 months ago

Psychedelic Stocks: Focus On Their Cash

MNMD

Aug 12, 2024, 12:12 PM EDT - 9 months ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CYBN MNMD

Aug 4, 2024, 1:22 AM EDT - 9 months ago

COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:30 AM EDT - 9 months ago

Compass Pathways announces second quarter 2024 financial results and business highlights

Jul 24, 2024, 7:01 AM EDT - 9 months ago

Compass Pathways to announce second quarter financial results on August 1, 2024

Jul 8, 2024, 10:11 AM EDT - 10 months ago

Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies

Jun 26, 2024, 6:30 AM EDT - 10 months ago

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Jun 24, 2024, 4:01 PM EDT - 10 months ago

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 23, 2024, 12:15 PM EDT - 11 months ago

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

MNMD

May 11, 2024, 5:31 PM EDT - 1 year ago

COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:45 AM EDT - 1 year ago

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 6:30 AM EDT - 1 year ago

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

May 3, 2024, 4:58 PM EDT - 1 year ago

Compass Pathways to announce first quarter financial results on May 8, 2024

May 2, 2024, 6:30 AM EDT - 1 year ago

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Apr 29, 2024, 6:30 AM EDT - 1 year ago

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Apr 1, 2024, 4:01 PM EDT - 1 year ago

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Feb 29, 2024, 11:43 AM EST - 1 year ago

COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Feb 26, 2024, 4:01 PM EST - 1 year ago

Compass Pathways to participate in upcoming TD Cowen investor conference

Feb 22, 2024, 4:01 PM EST - 1 year ago

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

Feb 8, 2024, 5:15 PM EST - 1 year ago

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Jan 31, 2024, 4:01 PM EST - 1 year ago

Compass Pathways to participate in upcoming Oppenheimer investor conference

Jan 16, 2024, 8:00 AM EST - 1 year ago

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Jan 9, 2024, 12:00 PM EST - 1 year ago

De-Risking Psychedelics: Compass Pathways, Cybin And Atai

MNMD

Jan 3, 2024, 11:17 AM EST - 1 year ago

Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this year

JNJ MNMD